Amicus Therapeutics Inc. (FOLD)
Company Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.
Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.
It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development.
The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline.
Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Country | United States |
IPO Date | May 31, 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 499 |
CEO | Bradley L. Campbell M.B.A. |
Contact Details
Address: 3675 Market Street Philadelphia, Pennsylvania United States | |
Website | https://amicusrx.com |
Stock Details
Ticker Symbol | FOLD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001178879 |
CUSIP Number | 03152W109 |
ISIN Number | US03152W1099 |
Employer ID | 20-0422823 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Bradley L. Campbell M.B.A. | Chief Executive Officer, President & Director |
David M. Clark | Chief People Officer |
Ellen S. Rosenberg J.D. | Chief Legal Officer & Corporate Secretary |
Simon Nicolas Reade Harford | Chief Financial Officer |
Andrew Faughnan | Senior Director of Investor Relations |
Diana Moore | Head of Global Corporate Communications |
Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer |
Dr. Jill Weimer Ph.D. | Chief Science Officer |
Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer |
Samantha Prout | Chief Accounting Officer & Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 18, 2025 | 4 | Filing |
Feb 21, 2025 | 4 | Filing |
Feb 21, 2025 | 8-K | Current Report |
Feb 21, 2025 | 424B5 | Filing |
Feb 19, 2025 | S-3ASR | Automatic shelf registration statement of securiti... |
Feb 19, 2025 | 10-K | Annual Report |
Feb 19, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Feb 13, 2025 | 4 | Filing |